TABLE 1.
Baseline characteristics of patients undergoing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR)
| Characteristic | TAVR (n = 168) |
SAVR (n = 259) |
P value |
|---|---|---|---|
| Age (y) | 81 ± 8 | 71 ± 11 | <.001 |
| Female | 92 (55) | 108 (42) | .010 |
| Body mass index | 27.5 ± 6.3 | 31 ± 8 | <.001 |
| Society of Thoracic Surgeons predicted risk of mortality score |
9.3 (6.1, 13.5) | 3.0 (1.5, 6.0) | <.001 |
| American Society of Anesthesiologists class ≥ 4 |
162 (96) | 180 (70) | <.001 |
| New York Heart Association functional class III–IV |
147 (88) | 139 (54) | <.001 |
| Diabetes mellitus | 72 (43) | 95 (37) | .220 |
| Hypertension | 156 (93) | 209 (81) | <.001 |
| Coronary artery disease | 143 (85) | 114 (44) | <.001 |
| Cerebrovascular disease | 52 (31) | 57 (22) | .040 |
| Atrial fibrillation | 65 (39) | 49 (19) | <.001 |
| Chronic lung disease* | 59 (35) | 39 (15) | <.001 |
| Peripheral vascular disease | 113 (67) | 71 (27) | <.001 |
| Ejection fraction (%) | 53 ± 15 | 58 ± 14 | .002 |
| Mean aortic valve gradient (mm Hg) |
44 ± 14 | 43 ± 14 | .700 |
| Preoperative glomerular filtration rate (mL/min) |
64 ± 27 | 75 ± 26 | <.001 |
| Hemoglobin (g/dL) | 11.3 ± 1.5 | 12.5 ± 1.9 | <.001 |
| Albumin (g/dL) | 4.0 ± 0.5 | 4.1 ± 4 | .120 |
Values are presented as mean ± standard deviation, n (%), or median (first quartile, third quartile).
TAVR, Transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement.
*
Moderate/severe.